Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MACH-1 HBV Vaccine (Immunocompromised)
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Epidermal
01
Overview
Orlance's MACH-1 HBV vaccine is a preclinical nucleic acid vaccine candidate specifically designed to address the unmet need for effective Hepatitis B virus (HBV) immunization in immunocompromised individuals. Utilizing the proprietary MACH-1 (Micro-particle Accelerated Delivery) platform, the vaccine is delivered epidermally via a powdered gene gun. This biolistic method propels DNA-coated gold micro-particles directly into the skin's epidermis, targeting the dense population of Langerhans cells and other antigen-presenting cells. By bypassing the limitations of traditional protein-based vaccines, which often fail to elicit protective antibody titers in patients with weakened immune systems (such as transplant recipients or HIV patients), this DNA-based approach aims to induce potent cellular and humoral immune responses. The platform is designed to be stable at room temperature and does not require a cold chain, potentially increasing accessibility.
- Other names
- MACH-1 hepatitis B vaccineMACH1 hepatitis B vaccineMACH 1 hepatitis B vaccineHBV-directed nucleic acid vaccine
Beyond the preview
Go deeper on MACH-1 HBV Vaccine (Immunocompromised).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MACH-1 HBV Vaccine (Immunocompromised).